Verteporfin , ≥97% , 129497-78-5

Synonym(s):
(4R,4aS)-rel-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-24H,26H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester;trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester;Visudyne

CAS NO.：129497-78-5

Empirical Formula: 2C41H42N4O8

Molecular Weight: 1437.61

MDL number: MFCD11982858

PRODUCT Properties

• storage temp.: -20°C
• solubility: DMSO: soluble2mg/mL, clear (warmed)
• form: powder
• color: Black
• Stability: Stable for 2 years from date of purchsae as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
• InChIKey: YHNBVDZVUQFVLS-RDSGBMLISA-N

Description and Uses

Verteporfin was introduced in Switzerland as a second-generation photosensitizer for photodynamic therapy of wet age-related macular degeneration in patients with subfoveal choroidal neovascularisation. It is constituted of a mixture of two regioisomers resulting from nonselective monohydrolysis of the methyl tetraester. Upon irradiation with a lowenergy nonheat-generating laser light of 689nm wavelength, both regioisomeric benzoporphyrins are responsible for the local generation of singlet oxygen leading to free radical damage of neovascular endothelial cells in subfoveal lesions of patients with agerelated macular degeneration. The lipophilic drug is injected i.v. as a liposomal formulation in order to favor its uptake by plasma lipoproteins and distribution to cells with a high expression of low density lipoprotein receptors such as tumor and neovascular endothelial cells. Verteporfin is also being developed for the treatment of other eye diseases, nonmelanoma skin cancer and psoriasis.

Treatment of age-related macular degeneration

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P280-P305+P351+P338
• WGK Germany: 3
• HS Code: 2933997500